Latest Share Chat

Glaxosmithkline Share News (GSK)

Glaxosmithkline Information

Buy GSK Shares
Add GSK to Watchlist
Add GSK to Alert

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 1,728.50

Bid: 1,727.00

Ask: 1,728.00

Change: 23.50 (1.38%)

Spread: 1.00 (0.058%)

Open: 1,705.00

High: 1,729.50

Low: 1,695.50

Prev. Close: 1,705.00

Last checked at -

GlaxoSmithKline accused of paying off competitors

Fri, 19th Apr 2013 11:10

GlaxoSmithKline (GSK) is being investigated over claims it paid off firms to delay the launch of cheap versions of its anti-depression drug, according to reports Friday.The UK's Office of Fair Trading (OFT) said GSK offered payments to Alpharma, Generics and Norton Healthcare, to postpone the release of rival medicines to its Seroxat treatment.The move denied the NHS significant cost savings, OFT alleged. GSK has been accused of abusing its dominant position in the market and breaking competition law. GSK's competitors were set to introduce a generic paroxetine product but they were suspected of infringing patents. In order to resolve the dispute, they agreed to be paid off by GSK, the OFT said. They are also being probed for allegedly overstepping competition law."The introduction of generic medicines can lead to strong competition on price, which can drive savings for the NHS, to the benefit of patients and, ultimately, taxpayers," said Ann Pope, Senior Director of Services, Infrastructure and Public Markets at the OFT."It is therefore particularly important that the OFT fully investigates concerns that independent generic entry may have been delayed in this case."GSK said it was co-operating with the OFT in its investigation which covers activities between 2001 and 2004. "GSK supports fair competition and we very strongly believe that we acted within the law, as the holder of valid patents for paroxetine, in entering the agreements under investigation," the group said in a statement."These arrangements resulted in other paroxetine products entering the market before GSK's patents had expired."Seroxat, one of GSK's best-selling medicines, has been whacked by generic competition in recent years. Sales fell 14% in 2012 to £374m and by nearly a fifth in the final three months of last year.Last year the company was fined $3.0bn in the US for paying medics to prescribe the drug for children even though was not intended for under 18s.RD

More News

3 Jan 2024 17:10

Latest Share Chat

Glaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

GlaxoSmithKline accused of paying off competitors

Miners, personal goods stocks drag FTSE 100 to two-week low

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

GSK buys rights to Hansoh Pharma antibody-drug conjugate

German court quashes CureVac patent after challenge by BioNTech

Energy stocks lift UK's FTSE 100, Vodafone shines

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

GSK sees success in Jemperli endometrial cancer trial

PRESS: GSK looks for deals in China as rebuilds relationship

Latest Share Chat

Glaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GlaxoSmithKline accused of paying off competitors

Login to your account

Quickpicks are a member only feature

Login to your account